Influenza, commonly referred to as the flu, is an infectious disease caused by RNA viruses of the
Orthomyxoviridae (the influenza viruses). Influenza A virus causes it and is the only species of influenza virus A. Influenza A viruses are negative sense, single-stranded, segmented RNA viruses. There are several subtypes, labeled according to an H number (for the type of hemagglutinin) and an N number (for the type of neuraminidase) (
1,
2). The influenza virus is a highly contagious virus that causes acute respiratory disease. Usually, influenza causes pneumonia which can be fatal in young patients or people with immunodeficiency. In addition, influenza is spread in seasonal epidemics throughout the world and kills countless people in pandemic years (
3).
Influenza A and B viruses are responsible for the vast majority of the 200000 to 500000 deaths and billions of US dollars in economic losses attributed to annual infections globally (
4,
5). The impact of factors such as age, sex and disease, on how individuals fight pathogens, lead to differences in the rate of occurrence, duration and severity of infections and diseases, particularly influenza (
6). In developed countries, such as the United States of America and Spain, the reported incidence of seasonal influenza virus infection is higher for males (up to 60% in the United States) than females of diverse ages, ranging from infants to elderly adults (
7).
Virus symptoms include upper respiratory system diseases such as sinusitis and otitis media, lower respiratory tract illnesses such as bronchitis, toxic shock syndrome, etc (
8). Typical clinical manifestations include fever, headache, cough, sore throat, myalgia as, chills, and fatigue. Diarrhea and vomiting may also occur (
9). Useful laboratory methods for diagnosis are RAT (Rapid Antigen Test) and RT-PCR (reverse-transcription polymerase chain reaction). RT-PCR is an optional test and has 98% sensitivity (
10). Antiviral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza) are effective against both influenza A and B (
11).
Studies have shown that a single dose of influenza vaccine A (H1N1) will increase safety, especially for elderly (
12-
17). In April 2009, the first case of influenza A H1N1 was registered in Mexico and lead to an unexpected number of deaths. This study reported the timing and spread of H1N1, and explored the protective and risk factors for infection, severe disease, and death. 63,479 cases of influenza-like illness were reported, from which 63 cases died (
18). When the 2009 H1N1 influenza A virus emerged in the United States, epidemiological and clinical information about severe and fatal cases was limited. One study reported the first 47 fatal cases of 2009 H1N1 influenza in New York City. In this study, which took place from the 24
th of April to the 1st of July 2009, 47 confirmed fatal cases of 2009 H1N1 influenza were reported to the New York City Department of Health and Mental Hygiene. Most decedents were aged between 18–49 years, and only 4% were aged up to 65 years (
19).
In another study Influenza-associated excess mortality for the period between 2003-2008 was estimated for three cities in temperate northern China and five cities in the subtropical south of the country. Most (86%) deaths occurred among people aged ≥ 65 years (
20). In another study Influenza A co infections with other respiratory viruses were investigated in 25.8% of the samples from patients hospitalized in 2009 at a hospital in Brazil. In this study co infection was not associated with higher morbidity or mortality (
21).